List of Excipients in Branded Drug OJJAARA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	OJJAARA	momelotinib	81864-103	CELLULOSE, MICROCRYSTALLINE	2030-09-15
GlaxoSmithKline LLC	OJJAARA	momelotinib	81864-103	FERRIC OXIDE RED	2030-09-15
GlaxoSmithKline LLC	OJJAARA	momelotinib	81864-103	FERRIC OXIDE YELLOW	2030-09-15

Ojjaara Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Ojjaara is the U.S. brand for momelotinib, an oral JAK1/JAK2 and activin A receptor type 1 inhibitor approved for adults with intermediate- or high-risk myelofibrosis and anemia. The product is supplied as immediate-release film-coated tablets in 100 mg, 150 mg, and 200 mg strengths, taken once daily with or without food.[1]

The excipient opportunity is primarily a supply-chain, generic-development, formulation-equivalence, and lifecycle-management opportunity. Ojjaara does not require a complex delivery system or biologic manufacturing platform. Its commercial durability depends more on momelotinib’s clinical differentiation, patent and regulatory exclusivity, and reliable tablet manufacturing than on a proprietary excipient technology.

What is Ojjaara and how does its formulation work?

Ojjaara contains momelotinib dihydrochloride monohydrate as the active pharmaceutical ingredient. The product is an immediate-release oral tablet. Its formulation objective is conventional: rapid disintegration, reproducible dissolution, adequate mechanical strength, dose uniformity, and acceptable film-coating performance.

Ojjaara dosage forms and administration

Attribute	Ojjaara
Active ingredient	Momelotinib
Dosage form	Immediate-release film-coated tablet
Strengths	100 mg, 150 mg, 200 mg
Administration	Once daily
Food requirement	May be taken with or without food
FDA approval	September 15, 2023
Sponsor at approval	GlaxoSmithKline
Main indication	Intermediate- or high-risk myelofibrosis with anemia
Regulatory category	Small-molecule pharmaceutical
Biosimilar pathway	Not applicable

The once-daily schedule creates a commercial preference for a robust, compact tablet with consistent release characteristics. A formulation that remains bioequivalent across the three strengths can reduce manufacturing complexity and support common tooling, shared excipient specifications, and efficient scale-up.

What excipients are used in Ojjaara tablets?

The U.S. prescribing information identifies conventional tablet excipients, including fillers, disintegrants, lubricants, glidants, and film-coating materials.[1] The exact excipient composition and quantitative amounts should be taken from the current approved labeling and the manufacturer’s regulatory documentation before commercial qualification.

Functional excipient categories

Excipient function	Commercial role in an Ojjaara-type formulation	Key technical concern
Diluent or filler	Provides tablet mass and supports compression	Compressibility, moisture sensitivity, supply consistency
Disintegrant	Promotes tablet breakup after administration	Disintegration-dissolution balance
Glidant	Improves powder flow during high-speed compression	Segregation and blend uniformity
Lubricant	Reduces punch-wall friction and ejection force	Over-lubrication can reduce dissolution
Film former	Creates a uniform protective and cosmetic coating	Adhesion, cracking, coating weight
Plasticizer	Improves coating flexibility	Migration and stability
Opacifier or pigment	Provides appearance and light protection	Batch-to-batch color control

The formulation uses established pharmaceutical excipient classes rather than a novel lipid, polymeric depot, osmotic, or nanoparticle system. That simplifies generic development but limits the ability to create a strong excipient-based barrier to competition.

What excipient strategy is appropriate for Ojjaara?

The optimal strategy is a low-risk, platform-based immediate-release tablet formulation.

1. Use compendial excipients with multiple suppliers

A manufacturer seeking a generic or authorized-generic platform should prioritize excipients with:

• United States Pharmacopeia or equivalent compendial status
• At least two qualified suppliers
• Established pharmaceutical-grade manufacturing
• Low variability in particle size and bulk density
• Documented elemental impurity, nitrosamine, and microbiological controls
• Reliable regional inventory

Multiple sourcing is particularly important for disintegrants, colloidal silicon dioxide, magnesium stearate, film-coating systems, and colorants. A formulation that depends on a single proprietary coating premix creates avoidable launch risk.

2. Control compression and dissolution rather than maximizing excipient novelty

The critical development work is likely to involve:

• Blend uniformity across the three strengths
• Tablet tensile strength
• Friability
• Disintegration time
• Dissolution under multiple pH conditions
• Sensitivity to lubricant concentration and mixing time
• Moisture uptake during storage
• Film-coat adhesion and color matching

For a small-molecule immediate-release product, dissolution performance is often the central formulation-equivalence risk. A generic formulation can use different excipients from the reference product if it meets applicable pharmaceutical equivalence and bioequivalence requirements, but excipient changes can alter wetting, disintegration, dissolution, and stability.

3. Consider a common-blend, strength-specific compression strategy

The three Ojjaara strengths may support one of two manufacturing approaches:

1. A common qualitative composition with proportional quantitative adjustments.
2. A common granulation or blend with strength-specific tablet weights.

The first approach can reduce development and validation burden. The second may improve dose uniformity or tablet dimensions if the API has challenging flow or compression properties. The preferred strategy depends on momelotinib particle characteristics, dose loading, and the reference product’s dissolution profile.

4. Use film coating as a product-identification tool

Color and imprinting are commercially important for a three-strength regimen. A robust film-coating system can reduce medication-error risk and support product differentiation in pharmacies and hospitals.

Potential coating suppliers include manufacturers of standard immediate-release coating platforms such as Colorcon, BASF, Evonik, and equivalent regional providers. The commercial opportunity is not necessarily a new coating chemistry. It is a qualified, reproducible coating system that can match the reference product while meeting global colorant and excipient regulations.

What commercial opportunities exist for Ojjaara excipient suppliers?

The strongest opportunities are in supply assurance, alternate-source qualification, and generic formulation support.

Excipient supply opportunities

Opportunity	Buyer	Commercial rationale
High-purity filler supply	Brand or generic manufacturer	Supports tablet mass and compression
Direct-compression grades	Generic developers	Reduces wet-granulation process burden
Superdisintegrant supply	Brand and generic manufacturers	Supports rapid tablet breakup
Lubricant and glidant packages	Contract manufacturers	Improves process robustness
Film-coating premixes	Brand, generic, and contract manufacturers	Simplifies color and coating control
Regional dual sourcing	Multinational manufacturers	Reduces geopolitical and logistics exposure
Excipient equivalence packages	Generic applicants	Supports formulation bridging and regulatory filings
Stability-indicating excipient services	CMC organizations	Addresses moisture, oxidation, and impurity risks

Excipient suppliers can also sell development services around design of experiments, process optimization, compaction modeling, dissolution mapping, and scale-up. These services are often more defensible than commodity excipient supply.

What generic entry risks exist for Ojjaara?

Generic entry risk is meaningful because Ojjaara is a conventional oral small molecule. The product does not have the manufacturing complexity associated with monoclonal antibodies, sterile injectables, inhaled products, or long-acting delivery systems.

A generic developer would typically evaluate:

• Abbreviated New Drug Application eligibility
• Reference-listed-drug selection
• Pharmaceutical equivalence
• Comparative dissolution
• Bioequivalence
• API particle-size control
• Tablet hardness and disintegration
• Film-coat similarity
• Labeling and indication carve-outs
• Orange Book-listed patents
• Paragraph IV certification risk

What formulation barriers could delay generic entry?

The main barriers are unlikely to be excipient scarcity. They are more likely to involve:

• Patent claims covering momelotinib or specific uses
• Difficulty reproducing the reference dissolution profile
• API supply and impurity control
• Strength-specific bioequivalence
• Stability under climatic conditions outside the U.S.
• Manufacturing scale-up across multiple tablet strengths
• Regulatory restrictions on protected method-of-use indications

A generic applicant may use a different excipient system if the resulting product meets the relevant regulatory requirements. Consequently, an excipient composition alone is unlikely to create a durable market barrier unless it is linked to a valid, enforceable formulation patent.

What patents protect Ojjaara’s formulation and commercial position?

Ojjaara’s commercial protection must be separated into four categories:

1. Composition-of-matter protection for momelotinib.
2. Method-of-use protection for myelofibrosis and anemia.
3. Formulation or dosage-form protection.
4. Regulatory exclusivity and Orange Book-listed patents.

The public product label establishes FDA approval and approved use, but it does not by itself establish the full patent estate. Patent numbers, expiration dates, terminal disclaimers, pediatric exclusivity, and current Orange Book listings must be assessed from the FDA Orange Book, USPTO records, and relevant court dockets.[2,3]

Orange Book and Paragraph IV exposure

Because Ojjaara is a small-molecule tablet, an ANDA applicant can potentially file a Paragraph IV certification against listed patents before their expiration. Litigation exposure would depend on:

• The scope of each listed claim
• Whether the applicant’s formulation practices fall within the claims
• Whether the proposed label requires a protected method of use
• Patent-term-adjustment calculations
• Any settlement or license agreement
• FDA approval timing after the 30-month stay

No biosimilar challenge applies. The relevant competitive pathway is generic substitution through an ANDA, not a 351(k) biosimilar application.

When does Ojjaara lose exclusivity?

Ojjaara’s exclusivity timeline has several separate components.

Protection	Relevance
FDA approval exclusivity	Depends on the statutory exclusivity category assigned at approval
Orphan-drug exclusivity	Potentially relevant if the approved indication received orphan designation
New chemical entity exclusivity	Depends on FDA classification of momelotinib
Patent exclusivity	Depends on issued claims and expiration calculations
Method-of-use patents	May delay unrestricted label competition but can permit carve-outs
Formulation patents	Relevant only if listed, valid, and infringed
Pediatric exclusivity	Could add six months if granted
Regulatory data protection	Depends on the FDA approval pathway and product classification

The FDA approved Ojjaara in 2023 for a defined myelofibrosis population.[1] Exact generic-entry dates should not be inferred from the approval date alone. They depend on the current Orange Book, approved supplements, patent-term adjustment, exclusivity codes, and litigation outcomes.

How strong is the Ojjaara patent estate?

From a formulation perspective, the estate is likely less defensible than the clinical and use-based protection because Ojjaara is an immediate-release tablet built from established excipient technologies.

Relative strength by protection type

Protection type	Expected strategic strength
Clinical differentiation in anemia	High commercial value
Momelotinib composition protection	Potentially high, subject to expiration and validity
Method-of-use claims	Moderate to high if narrowly tied to anemia and myelofibrosis
Conventional excipient formulation	Low to moderate
Film-coating color and appearance	Low legal strength, higher branding value
Manufacturing process	Moderate if claims cover difficult API or impurity controls
Supply-chain qualification	Commercially useful but not patent exclusivity

A formulation patent becomes more valuable if it claims a measurable performance advantage, such as improved stability, reduced impurity formation, or a defined dissolution profile that is difficult to reproduce. A patent directed only to a conventional mixture of common fillers, disintegrants, lubricants, and coating agents would face greater validity and design-around pressure.

How does Ojjaara compare with competing myelofibrosis therapies?

Ojjaara occupies a differentiated position because it is approved for patients with myelofibrosis and anemia, a population in which treatment-related cytopenias can restrict use of other JAK inhibitors.

Product	Active ingredient	Form	Excipient complexity	Competitive consideration
Ojjaara	Momelotinib	Immediate-release tablet	Conventional	Anemia-focused positioning
Jakafi	Ruxolitinib	Immediate-release tablet	Conventional	Established JAK inhibitor
Inrebic	Fedratinib	Oral capsule	Conventional solid oral	Alternative JAK2-directed therapy
Vonjo	Pacritinib	Oral capsule	Conventional solid oral	Positioning in severe thrombocytopenia

The excipient strategy across this class is broadly similar: conventional solid oral dosage forms, standard excipients, and manufacturing processes that can be replicated by generic developers. Product differentiation therefore depends mainly on clinical profile, labeling, prescriber preference, market access, and intellectual property.

What manufacturing and licensing opportunities exist?

Commercial opportunities include:

Contract manufacturing

Contract development and manufacturing organizations can offer:

• API-to-tablet process development
• Multi-strength compression
• Film-coating scale-up
• Comparative dissolution programs
• Stability studies
• Commercial packaging
• Regional regulatory support

Licensing

Licensing opportunities may involve:

• Regional commercialization rights
• Authorized-generic arrangements
• Generic development partnerships
• Excipient or coating technology licenses
• Co-development of pediatric or modified-release presentations
• Technology transfer to emerging-market manufacturers

A modified-release or alternate dosage form would require a clear clinical or adherence benefit. A new presentation without a meaningful therapeutic advantage would face limited commercial justification.

What is the FDA regulatory status of Ojjaara?

Ojjaara was approved by FDA on September 15, 2023, for adults with intermediate- or high-risk myelofibrosis with anemia.[1] The product is an oral small-molecule medicine, so FDA regulatory analysis centers on the NDA, postmarketing requirements, supplements, labeling, and generic ANDA pathway.

The FDA label also includes clinically important warnings and drug-interaction considerations. These may influence formulation development if excipients affect absorption, tolerability, or dose administration. The approved product’s ability to be taken with or without food reduces the commercial value of a formulation that depends on a narrowly controlled meal condition.

Key Takeaways

• Ojjaara is a conventional immediate-release momelotinib tablet in 100 mg, 150 mg, and 200 mg strengths.
• The primary excipient opportunity is supply assurance and generic-development support, not a novel delivery platform.
• Direct-compression fillers, superdisintegrants, lubricants, glidants, and film-coating systems are the most commercially relevant excipient categories.
• Generic entry risk is material because the product is a small-molecule oral tablet with no biosimilar barrier.
• The strongest commercial protection is likely to come from momelotinib composition, clinical use, regulatory exclusivity, and market positioning rather than conventional excipient selection.
• Excipient suppliers can capture value through dual sourcing, formulation-equivalence packages, dissolution optimization, and contract manufacturing.
• Exact patent expiration and generic-entry dates require current Orange Book and USPTO review.

FAQs

Can a generic Ojjaara use different excipients?

Yes. A generic applicant may use a different excipient composition if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements.

Is Ojjaara a biologic eligible for biosimilar competition?

No. Ojjaara contains momelotinib, a chemically synthesized small molecule. Competition would proceed through generic-drug pathways rather than the biosimilar pathway.

Could an excipient patent block generic momelotinib?

Potentially, but only if a valid, enforceable claim covers the proposed generic formulation and the patent is relevant to FDA-listed protection. Conventional excipient combinations are generally easier to design around than specialized delivery systems.

Which excipients are most important for Ojjaara tablet performance?

The most important categories are the filler, disintegrant, lubricant, glidant, and film-coating system. Their particle size, moisture profile, mixing behavior, and concentration can affect compression, disintegration, dissolution, and stability.

Is a pediatric Ojjaara formulation a significant commercial opportunity?

It could be, particularly if a lower-dose, dispersible, or liquid presentation improves administration in younger patients. The opportunity depends on pediatric development, approved labeling, stability, palatability, dosing flexibility, and regulatory exclusivity.

References

1. U.S. Food and Drug Administration. (2023). Ojjaara (momelotinib) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment records.
4. GlaxoSmithKline plc. (2024). Annual report 2023.